6,800 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Prakash Investment Advisors LLC

Prakash Investment Advisors LLC bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 4th quarter, HoldingsChannel.com reports. The fund bought 6,800 shares of the company’s stock, valued at approximately $283,000.

A number of other large investors also recently modified their holdings of MRNA. Blue Trust Inc. boosted its holdings in shares of Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after buying an additional 574 shares in the last quarter. Raymond James & Associates boosted its stake in Moderna by 19.7% during the 3rd quarter. Raymond James & Associates now owns 162,074 shares of the company’s stock worth $10,831,000 after purchasing an additional 26,657 shares during the period. Commerzbank Aktiengesellschaft FI boosted its stake in Moderna by 9.7% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 6,087 shares of the company’s stock worth $407,000 after purchasing an additional 537 shares during the period. International Assets Investment Management LLC boosted its stake in Moderna by 10,687.1% during the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after purchasing an additional 316,552 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in Moderna by 79.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 13,159 shares of the company’s stock worth $879,000 after purchasing an additional 5,807 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Stock Down 6.0 %

Shares of MRNA opened at $33.73 on Friday. The company has a 50-day simple moving average of $38.17 and a 200-day simple moving average of $53.20. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The company has a market capitalization of $12.98 billion, a PE ratio of -3.63 and a beta of 1.59.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last three months, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

MRNA has been the subject of a number of recent research reports. Berenberg Bank increased their price target on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday, January 16th. Bank of America cut their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. JPMorgan Chase & Co. cut their price objective on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a research report on Tuesday, November 26th. Royal Bank of Canada restated a “sector perform” rating and set a $40.00 price objective on shares of Moderna in a research report on Tuesday. Finally, Wolfe Research assumed coverage on shares of Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.